Tarlatamab is a bispecific T-cell engager (BiTE) that binds to delta-like ligand-3 (DLL3) on small cell lung cancer (SCLC) cells and cluster of differentiation-3 on T cells, thereby delivering ...

Healio: Reshmi Parameswaran, assistant professor at the School of Medicine, discussed research into BAFF ligand-based CAR T-cell therapy. “Given my previous experience with BAFF receptor antibodies as ...

Because many different types of cancer cells overexpress programmed death-ligand 1 (PD-L1), this cell surface protein is a ...

Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...

Because many different types of cancer cells overexpress programmed death-ligand 1 (PD-L1), this cell surface protein is a major target of cancer immunotherapy. Unfortunately, drugs that target it do ...

A cell-specific gene therapy has been shown to silence pain encoding neurons in mice, offering a potential alternative to ...

The therapeutic landscape of small cell lung cancer (SCLC) is undergoing a paradigm shift with the emergence of delta-like ligand-3 (DLL3)–directed therapies, particularly tarlatamab, a first-in-class ...